Statistical methods in immunology & rheumatology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
ANCOVA
Odds ratio
Multiple imputation / missing data
Cochran-Mantel-Haenszel test
Mixed-effects model
Logistic regression
MMRM (mixed model for repeated measures)
Risk difference
All immunology & rheumatology trials
1,062 results
- Heart Failure Polypill at a Safety Net Hospital: Complete Statistical AnalysisIndependent statistical analysis of Heart Failure Polypill at a Safety Net Hospital: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06029712).
- HEORIndependent statistical analysis of Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Herbal Treatment for Perennial Allergic Rhinitis: Complete Statistical AnalysisIndependent statistical analysis of Herbal Treatment for Perennial Allergic Rhinitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00456755).
- High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin’s Lymphoma or Central Nervous System (CNS) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- High Frequency Impulse Therapy for Neuropathic Pain in NMOSD: Complete Statistical AnalysisIndependent statistical analysis of High Frequency Impulse Therapy for Neuropathic Pain in NMOSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04614454).
- High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00349778).
- High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- HIPPERIndependent statistical analysis of Feasibility of the Hip Instructional Prehabilitation Program for Enhanced Recovery (HIPPER): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- HIV and Kidney Function Study: Complete Statistical AnalysisIndependent statistical analysis of HIV and Kidney Function Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00905151).
- HIV Vaccine Trial in Thai Adults: Complete Statistical AnalysisIndependent statistical analysis of HIV Vaccine Trial in Thai Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00223080).
- Home Based Daratumumab Administration for Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Home Based Daratumumab Administration for Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05511428).
- Home-based tDCS and Mindfulness-based Meditation for Self-management of Clinical Pain and Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Home-based tDCS and Mindfulness-based Meditation for Self-management of Clinical Pain and Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- HVTN 120Independent statistical analysis of Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants: primary endpoint results, effect estimate with confidence interval,…
- Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02463097).
- Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients: Complete Statistical AnalysisIndependent statistical analysis of Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ICEIndependent statistical analysis of Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00220740).
- ICONIC-TOTALIndependent statistical analysis of A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet):…
- Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant: Complete Statistical AnalysisIndependent statistical analysis of Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IDEALEIndependent statistical analysis of Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study):…
- Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- IGNAZIndependent statistical analysis of Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- IHAIndependent statistical analysis of Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IKEMAIndependent statistical analysis of Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients: primary endpoint results, effect estimate with confidence interval, sample-size…
- IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT: Complete Statistical AnalysisIndependent statistical analysis of IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA: Complete Statistical AnalysisIndependent statistical analysis of IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ILA115938Independent statistical analysis of Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- IMAGEIndependent statistical analysis of A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Imaging in MGUS, SMM and MM: Complete Statistical AnalysisIndependent statistical analysis of Imaging in MGUS, SMM and MM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01237054).
- iMALTIndependent statistical analysis of Improving Medication Adherence in Adolescents Who Had a Liver Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03691220).
- IMARA-SA pilotIndependent statistical analysis of A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions: Complete Statistical AnalysisIndependent statistical analysis of Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immediate Effects of rTMS on Excitability of the Quadriceps With Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Immediate Effects of rTMS on Excitability of the Quadriceps With Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- IMPACTIndependent statistical analysis of An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients: Complete Statistical AnalysisIndependent statistical analysis of Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program: Complete Statistical AnalysisIndependent statistical analysis of Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- IMPOSEIndependent statistical analysis of Impulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor Initiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Improving Resilience and Longevity for Workers Through Exercise: Complete Statistical AnalysisIndependent statistical analysis of Improving Resilience and Longevity for Workers Through Exercise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03050320).
- Improving Treatment Adherence in HIV-Infected Individuals: Complete Statistical AnalysisIndependent statistical analysis of Improving Treatment Adherence in HIV-Infected Individuals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00247611).
- INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Increasing Activity in Liver Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Increasing Activity in Liver Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02058498).
- Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED): Complete Statistical AnalysisIndependent statistical analysis of Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- INDUMAIndependent statistical analysis of Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00207142).